EORTC Group phase II study of oral etoposide for pretreated soft tissue sarcoma

Sarcoma

Volumn 1, Issue 2, 1997, Pages 99-101

  Keizer, H Jan ^a   Crowther, Derek ^b   Nielsen, Ole Steen ^c   Van Oosterom, Allan T ^d   Muguiro, Javier Hornedo ^e   Van Pottelberghe, Christine ^f   Somers, Renier ^g   Tursz, Thomas ^h  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e Hospital Universitario Madrid   (Spain)

^f EORTC DATA CENTER   (Belgium)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Etoposide; Pretreated; Soft tissue sarcoma

Indexed keywords

EID: 0002486065     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577149778371     Document Type: Article

References (7)

1. Hainsworth JD, Greco FA. Etoposide: twenty years later. Ann Oncol 1995; 6:325-41.
2. Slevin ML, Clark PI, Osborne RJ, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1990; 7:1333-40.
3. Dombernowsky P, Buesa J, Pinedo HM, et al. VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1987; 23:579-80.
4. Welt S, Magill GB, Sordillo PP, et al. Phase II trial of VP-16-213 in adults with advanced soft tissue sarcomas. Proc Am Soc Clin Oncol 1983; 3:234.
5. Saeter G, Talle K, Solheim ØP. Treatment of advanced high-grade soft tissue sarcoma with ifosfamide and continuous infusion etoposide. Cancer Chemother Pharmacol 1995; 36:172-5.
6. Kampe CE, Löwenbraun S, Foster J, et al. Oral etoposide in treatment of advanced refractory sarcomas. J Natl Cancer Inst 1992; 84:1836-7.
7. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily administration of oral etoposide - a phase I trial. J Clin Oncol 1989; 8:396-401.